We are studying whether nintedanib can help reduce the duration of nosebleeds in patients with hereditary hemorrhagic telangiectasia. The trial also examines its effects on quality of life and potential side effects.
Health conditions and diseases that the clinical trial is designed to study and treat.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that causes abnormal blood vessel formation, leading to symptoms such as frequent nosebleeds, skin lesions, and potential complications in organs due to vascular malformations.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.